Heart hope for HS patients: drug may slow artery plaque
NCT ID NCT07454889
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study follows 34 adults with moderate-to-severe hidradenitis suppurativa (HS) who are taking secukinumab as part of their routine care. Researchers will use a special CT scan to check if the drug affects the buildup of plaque in the heart arteries over 12 months. The goal is to see if treating HS inflammation might also help keep the heart healthier.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- secukinumab
- What this could lead to
- If successful, this could suggest that treating HS with secukinumab may also help stabilize or prevent heart artery plaque, pointing to broader heart benefits.
- What could go wrong
- This is a small, single-center observational study, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could childhood trauma fuel skin inflammation?
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition